c-Met
Avistone Biotechnology to Launch Phase I Trial of c-MET Inhibitor in Canada
Canadian health authorities cleared the firm's application to study ANS01 as treatment for advanced solid tumor patients harboring various MET alterations.
AbbVie's Telisotuzumab Vedotin Effective in NSCLC Patients With High, Intermediate c-MET Expression
Premium
The Phase II results bolster the firm's confidence in the c-MET expression cutoff it has established in an ongoing Phase III trial of the drug.
Avistone Biotechnology, Apollomics Net c-Met Inhibitor Approval for Certain Glioma Patients in China
The NMPA approved the drug for patients with IDH-mutant astrocytoma or glioblastoma with PTPRZ1-MET gene fusions who have failed previous treatments.
AbbVie Eyeing Accelerated Approval Pathway for c-Met-Targeted Antibody-Drug Conjugate in NSCLC
In the LUMINOSITY trial, patients with EGFR wild-type advanced NSCLC had overall response rates of 23 percent to 35 percent based on their level of c-Met overexpression.
Apollomics Vebreltinib Approved in China for MET-Altered NSCLC
The NMPA approved the c-MET inhibitor based on results from a Phase II study in Chinese patients demonstrating a 75 percent response rate.